PAR IO- A COST ANALYSIS OF CELECOXIB VERSUS DICLOFENAC PLUS OMEPRAZOLE FORTHE TREATMENT OF ARTHRITIS IN A GROUP OF HIGH-RISK CHINESE PATIENTS

May 1, 2003, 00:00 AM
10.1016/S1098-3015(10)63911-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)63911-3/fulltext
Section Title :
Section Order : 112
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63911-3&doi=10.1016/S1098-3015(10)63911-3
HEOR Topics :
Tags :
Regions :